Menu

Recent Interviews

Jerre Foo, Corporate Development Executive, Silkroad Nickel

Jerre Foo
Corporate Development Executive | Silkroad Nickel
50 Armenian Street #03-04, 179938 Singapore (SGP)

enquiries@silkroadnickel.com

+65 6327 8971

Silkroad Nickel: 'The course is set for dynamic profit growth.'


Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG

Dr. Thomas Gutschlag
CEO | Deutsche Rohstoff AG
Q7, 24, 68161 Mannheim (D)

info@rohstoff.de

+49 621 490 817 0

Interview Deutsche Rohstoff AG: "We can imagine additional investments in the field of electromobility."


Steve Cope, President, CEO and Director, Silver Viper

Steve Cope
President, CEO and Director | Silver Viper
1055 W Hastings St Suite 1130, V6E 2E9 Vancouver (CAN)

info@silverviperminerals.com

+1-604-687-8566

Interview with Silver Viper: Future price drivers and takeover fantasy


01. December 2020 | 09:54 CET

Desert Gold, BioNTech, Vodafone - Healthier, Cleaner, Gold!

  • Investments
Photo credits: pixabay.com

Asian stocks have recently faltered near their record highs, but the Nikkei, in particular, has experienced a grand rally of 15% in the last 4 weeks. Yesterday 30.11. is a popular settlement day for fund managers around the globe because from this date on you only have 1 month to clean the portfolio from unwanted components. In simple terms, stocks which ran poorly all year are likely to be sold and stocks that everyone's talking about and have performed well so far, tend to be topped up again. Among asset management experts, these measures are called "window dressing", i.e., perfecting the design of the viewing rooms in the form of a portfolio listing.

On the market as a whole, investors seem to be developing the view that the economic recovery will gain momentum next year, and this is driving some to liquidate their gold holdings - intended as a security investment - rather than to sell them. On the technical front, support for gold remains intact at around USD 1,750 to USD 1,770 an ounce. Silver continues to see massive interest near the psychological level of USD 22-23, the Technical Analysis tells us. Whether we can take this as a given at the end of the year remains to be seen; the pressure on precious metals prices is currently high.

time to read: 4 minutes by André Will-Laudien


 

Author

André Will-Laudien

Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

About the author


Desert Gold - The Africa fantasy remains

Although the Desert Gold stock has been quiet in recent weeks, preparations for a new exploration program are in full swing. The funds from the last transaction are still available with traded prices of well over CAD 0.30. A capital increase at CAD 0.28 could be placed, and CAD 6.5 million could be raised.

The company is surrounded by big names like B2Gold and Barrick Gold. West Africa is the place to be for exploration and production. The huge upside potential for discoveries makes Mali very attractive for junior exploration companies like Desert Gold. The team already explored gold in the past and knows where to drill in the upcoming program. With the money in the bank, the company is very flexible and can focus on increasing the gold reserves.

At the current price of CAD 0.14, the most recently depressed value has a capitalization of only CAD 18.5 million. Chart Technically, one is here broadly supported, but at present the tax loss realizations customary in Canada, dominate. In our view, there is, therefore, a clear chance of doubling in the next gold rebound.

BioNTech - December is the time

The UK is on the verge of becoming the first country to approve the Covid-19 vaccine from Pfizer Inc. and BioNTech SE, ahead of a long line of countries waiting for protection against the coronavirus. The release is possible as early as the beginning of December, said a person familiar with the situation who asked not to be revealed, as the process is still highly confidential. Earlier last week, the Health Commission MHRA announced that it now has the data it needs to release the vaccine. Nevertheless, the studies will continue to gradually increase their validity, thus documenting the thoroughness of further review.

The vaccine was already 95% effective in a clinical study involving almost 44,000 people, and so far, there have been no significant safety problems. The first vaccines to a broader audience are likely to be administered as of December 7, the Financial Times reported.

The UK has ordered enough doses of the Pfizer BioNTech dual-dose vaccine to immunize 20 million people, although this amount will almost certainly not be available immediately. The two Companies responsible have also signed contracts to supply hundreds of millions of vaccines to Europe, the US, Japan and other countries.

Pfizer-BioNTech's vaccine has moved to the top of the field after delays in testing a vaccine from AstraZeneca Plc and the University of Oxford. Another vaccine from Moderna Inc. has also proven its high efficacy in trials.

The BioNTech share was recently able to advance several times into the region of USD 120. With a capitalization of USD 25 billion for a product, one wonders whether all fantasy is not already priced in - but after all, the high volatility of the share not only offers investors fun but is also suitable for every gambler. BioNTech has already increased sixfold in 2020.

Vodafone - Clean radio here

Vodafone PLC announced a voluntary commitment to reduce global carbon emissions to zero by 2040. By 2030, Vodafone will already have eliminated all emissions from its own activities and from the energy mix it uses, after which the issues of waste avoidance and business travel will be on the agenda. Such green statements are a rarity from the telecommunications industry. After all, what destroys the environmental image more than the radio masts placed arbitrarily in the landscape, which will soon be chasing lush 5G frequencies into the ether. A fancy future design of these masts has not been sighted yet.

The telecommunications giant said these targets have been endorsed by the Science-Based Targets initiative, supported by the United Nations and WWF, among others, and are consistent with the reductions needed to keep global warming at 1.5°C, the most ambitious goal of the Paris Accord. As early as July 2021, Vodafone's European network will be powered 100% by renewable energy sources, creating a green gigabit network for customers in the 11 target markets, which will grow sustainably and use electricity sources exclusively from wind, solar or hydropower.

The underlying strategy is obvious: ESG pressure is very high among Vodafone's customers and not least, among the telecommunications giants themselves, to switch their traditional business model to a sustainable one. The measure that immediately comes to mind is, of course, electricity consumption. Thanks to the sustainable changes in Vodafone's strategy, its customers can already take on all the upfront costs of using the service provider and then slide up the ESG scale as well.

So the Board of Management naturally, proudly and politically correct announces: "Vodafone will also enable our customers to reduce their ecological footprint by using our services, including the Internet of Things". Bravo - we investors are pleased to hear that! Now Vodafone, too, is gaining access to the modern ESG portfolios of sustainably oriented major investors.

The market capitalization of Vodafone PLC is currently GBP 33.5 billion, but high debt remains a problem. On the charts, the share price has already sent out very positive signals with an increase of 19% since the end of October.


Author

André Will-Laudien

Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

20. April 2021 | 09:45 CET | by Stefan Feulner

Varta, Sierra Growth, CureVac - Clear signals!

  • Investments

Sometimes, for various reasons, it takes longer before the positive developments of a Company are absorbed by the market and thus provide for price gains. It is currently similar to the precious metal gold, which is still in the consolidation phase. The facts such as national debt, inflation fears and the ultra-loose monetary policy of the central banks speak another clear language.

Read

20. April 2021 | 07:10 CET | by Carsten Mainitz

BioNTech, SunMirror, Steinhoff - Great News!

  • Investments

Shortly before the finish line, the going gets tough again. Many athletes and those who have to really "bite" in the last few meters before a deadline are probably familiar with this feeling. Everyday life in the Corona pandemic is also becoming more exhausting. Now, with BioNTech's announcement that it will double weekly vaccine dose deliveries to around 5.1 million units from the end of May, there may be a breakthrough in achieving herd immunity in Germany in the next few months. It is not only good news for the Company's shareholders but everyone. Below we present two other companies whose shareholders should be very pleased. Let us surprise you!

Read

15. April 2021 | 07:15 CET | by Stefan Feulner

Alibaba, The Place Holdings, CureVac - Great opportunities lie here!

  • Investments

The German vaccination disaster is going into the next round. After the AstraZeneca vaccine's back and forth and the question of whether only younger people, older people or no one should be vaccinated with the vaccine, the American vaccine manufacturer Johnson & Johnson is now experiencing delivery stoppages. The return to "normality" once again seems to be a long way off. Another question to ask yourself. What will future life in the new normal look like in the hard-pressed inner cities?

Read